ArdyDavarifarMDPhD

Oncology • Knoxville, TN

Hematologic Oncology

Physician

Join to view full profile

Dr. Davarifar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davarifar's full profile

Already have an account?

Office
1926 Alcoa Hwy
Suite 350
Knoxville, TN 37920
Phone+1 865-305-8780

Fax+1 865-305-8199

Summary

Dr. Ardy Davarifar is an oncology specialist based in Knoxville, TN, with a subspecialty in hematologic oncology. He completed his hematology and medical oncology fellowship at UCLA David Geffen School of Medicine/UCLA Medical Center from 2018 to 2022, with an additional year of dedicated postdoctoral research in precision oncology as a STAR awardee. He graduated from Albert Einstein College of Medicine in 2015 and completed his residency in internal medicine at New York Presbyterian Hospital (Columbia Campus) from 2015 to 2018. Dr. Davarifar has authored multiple publications, with topics ranging from drug sensitivity in sarcoma to personalized chordoma organoids, reflecting his extensive involvement in oncology research.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2018 - 2022
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2015 - 2018
Albert Einstein College of MedicineClass of 2015

Certifications & Licensure

TN State Medical License 2022 - 2027
CA State Medical License 2018 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

STAR Award UCLA, 2018-2022

Clinical Trials

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) Start of enrollment: 2024 Jul 11
RECRUITING
PHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Start of enrollment: 2023 Dec 21
RECRUITING
PHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Start of enrollment: 2023 Jun 28
RECRUITING
PHASE3
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2024 Nov 18
RECRUITING
PHASE2
Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer Start of enrollment: 2025 Jan 07
RECRUITING
PHASE2, PHASE3
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC Start of enrollment: 2024 Dec 26
RECRUITING
PHASE2
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) Start of enrollment: 2024 Nov 25
RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

2 citations
The landscape of drug sensitivity and resistance in sarcoma.
Ahmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini
Cell Stem Cell. 2024-10-03
42 citations
Drug screening at single-organoid resolution via bioprinting and interferometry.
Peyton J Tebon, Bowen Wang, Alexander L Markowitz, Ardalan Davarifar, Brandon L Tsai
Nature Communications. 2023-06-06
34 citations
Personalized chordoma organoids for drug discovery studies.
Ahmad Al Shihabi, Ardalan Davarifar, Huyen Thi Lam Nguyen, Nasrin Tavanaie, Scott D Nelson
Science Advances. 2022-02-18

Abstracts/Posters

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC)
A. Davarifar, C. Gordon, I. Oliff, T. Huang, W. Zheng, B. Wang, D. Skokos, F. A. Seebach, I. Lowy, M. Mathias, M. Kinnaman, E. Kim, E. Miller, M. Ingham, ASCO, CHICAGO, 5/2025
A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced ...
J. J. Luke, C. Robert, A. Davarifar, Y. G. Najjar, O. Hamid, C. A. Nebhan, D. C. Portnoy, D. Schadendorf, M. K. Wong, N. I. Khushalani, P. Ascierto, T. L. Bowles, M. N..., Melanoma Research Alliance (MRA) Scientific Retreat, Washington DC, 2/2025
Abstract 5682: A reconstruction of evolutionary trajectories in primary tissue and PDTOs in a patient with metastatic osteosarcoma
Davarifar, A., Yanagawa, J., Nguyen, H. T., Tavanaie, N., Federman, N., Bernthal, N., Nelson, S., Hornicek, F., Boutros, P., Soragni, A, AACR, New Orleans, 4/2022
Abstract 5484: A pipeline for functional precision medicine in bone and soft tissue sarcoma organoids
Al Shihabi, A., Tebon, P., Chantharasamee, J., Nguyen, H., Sartini, S., Davarifar, A., Tavanaie, N., Nelson, S., Federman, N., Yanagawa, J., Soragni, A, AACR, New Orleans, 4/2022
Abstract 5245: High-speed live cell interferometry captures heterogeneity in bioprinted tumor organoids
Tebon, P., Wang, B., Markowitz, A., Murray, G., Davarifar, A., Nguyen, H., Tavanaie, N., Nguyen, T., Boutros, P., Teitell, M., Soragni, A., AACR, New Orleans, 4/2022
Join now to see all

Lectures

Immunotherapy Options in Esophageal Adenocarcinoma
UT Big 4 Conference - 9/2023

Research History

Postdoctoral ResearchConducted whole-genome computational analysis for a pediatric osteosarcoma patient, tracking evolutionary trajectories and treatment responses across longitudinal samples and patient-derived tumor organoids.2020 - 2022
Postdoctoral ResearchDeveloped comprehensive databases and data visualization platforms for high-throughput drug screenings in patient-derived tumor organoids. Implemented an image segmentation neural network (U-net) and cell-tracking algorithms to quantify tumor organoid growth responses to therapeutics.2020 - 2022
Doctoral researchExplored lactate dehydrogenase (LDH) enzyme dynamics, highlighting a novel energy-transfer pathway essential for catalytic activity. Findings have inspired further research toward identifying potential therapeutic inhibitors for cancers reliant on anaerobic metabolism.2009 - 2013